Literature DB >> 18990075

The good, the bad and the ugly: how altered peptide ligands modulate immunity.

Maria Katsara1, Gabriela Minigo, Magdalena Plebanski, Vasso Apostolopoulos.   

Abstract

BACKGROUND: The basis of T cell immune responses is the specific recognition of an immunogenic peptide epitope by a T cell receptor. Peptide alterations of such T cell epitopes with single or few amino acid variations can have drastic effects on the outcome of this recognition. These altered peptide ligands can act as modulators of immune responses as they are capable of downregulating or upregulating responses. OBJECTIVE/
METHODS: We review how altered peptide ligands can have 'good' 'bad' and 'ugly' outcomes in treating diseases. RESULTS/
CONCLUSION: Altered peptide ligands have been used as immunotherapeutics in autoimmune (and allergic) diseases, infectious diseases and cancer. In the next five years we anticipate seeing a number of altered peptide ligands in clinical trials, progressing from contradictory classifications of good, bad or ugly, to the exciting outcome of 'useful'.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18990075     DOI: 10.1517/14712590802494501

Source DB:  PubMed          Journal:  Expert Opin Biol Ther        ISSN: 1471-2598            Impact factor:   4.388


  18 in total

Review 1.  Improving T cell responses to modified peptides in tumor vaccines.

Authors:  Jonathan D Buhrman; Jill E Slansky
Journal:  Immunol Res       Date:  2013-03       Impact factor: 2.829

2.  A broadly applicable approach to T cell epitope identification: application to improving tumor associated epitopes and identifying epitopes in complex pathogens.

Authors:  Michael D Valentino; C Siddiq Abdul-Alim; Zachary J Maben; Denise Skrombolas; Lucinda L Hensley; Thomas H Kawula; Michelle Dziejman; Edith M Lord; Jeffrey A Frelinger; John G Frelinger
Journal:  J Immunol Methods       Date:  2011-08-18       Impact factor: 2.303

3.  Stimulation of naive CD8+ T cells by a variant viral epitope induces activation and enhanced apoptosis.

Authors:  Rebecca M Ream; Jie Sun; Thomas J Braciale
Journal:  J Immunol       Date:  2010-02-05       Impact factor: 5.422

4.  Enhancing Antigen Presentation and Inducing Antigen-Specific Immune Tolerance with Amphiphilic Peptides.

Authors:  Meng Li; Arata Itoh; Jingchao Xi; Chunsong Yu; Yuehong Wu; William M Ridgway; Haipeng Liu
Journal:  J Immunol       Date:  2021-09-15       Impact factor: 5.426

5.  DNA vaccines encoding altered peptide ligands for SSX2 enhance epitope-specific CD8+ T-cell immune responses.

Authors:  Heath A Smith; Brian T Rekoske; Douglas G McNeel
Journal:  Vaccine       Date:  2014-01-31       Impact factor: 3.641

6.  West Nile virus T-cell ligand sequences shared with other flaviviruses: a multitude of variant sequences as potential altered peptide ligands.

Authors:  Keun-Ok Jung; Asif M Khan; Benjamin Yong Liang Tan; Yongli Hu; Gregory G Simon; Eduardo J M Nascimento; Francois Lemonnier; Vladimir Brusic; Olivo Miotto; Tin Wee Tan; Ernesto T A Marques; Rafael Dhalia; Jerome Salmon; J Thomas August
Journal:  J Virol       Date:  2012-05-09       Impact factor: 5.103

7.  An Altered gp100 Peptide Ligand with Decreased Binding by TCR and CD8α Dissects T Cell Cytotoxicity from Production of Cytokines and Activation of NFAT.

Authors:  Niels Schaft; Miriam Coccoris; Joost Drexhage; Christiaan Knoop; I Jolanda M de Vries; Gosse J Adema; Reno Debets
Journal:  Front Immunol       Date:  2013-09-04       Impact factor: 7.561

Review 8.  Targeting antigens to dendritic cell receptors for vaccine development.

Authors:  Vasso Apostolopoulos; Theresia Thalhammer; Andreas G Tzakos; Lily Stojanovska
Journal:  J Drug Deliv       Date:  2013-10-08

9.  Active immunization with myelin-derived altered peptide ligand reduces mechanical pain hypersensitivity following peripheral nerve injury.

Authors:  Chamini J Perera; Samuel S Duffy; Justin G Lees; Cristina F Kim; Barbara Cameron; Vasso Apostolopoulos; Gila Moalem-Taylor
Journal:  J Neuroinflammation       Date:  2015-02-13       Impact factor: 8.322

Review 10.  Peptide Dose and/or Structure in Vaccines as a Determinant of T Cell Responses.

Authors:  Graham R Leggatt
Journal:  Vaccines (Basel)       Date:  2014-07-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.